Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment

Primary refractory diffuse large B cell lymphoma (DLBCL) following R-CHOP chemotherapy is a major concern. We identified 1126 patients with DLBCL treated with R-CHOP from 2000 to 2009, of whom 166 (15 %) had primary refractory disease. Of the 75/166 (45 %) who were age

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Annals of hematology 2015-11, Vol.94 (11), p.1839-1843
Hauptverfasser: Hitz, Felicitas, Connors, J. M., Gascoyne, R. D., Hoskins, P., Moccia, A., Savage, K. J., Sehn, L. H., Shenkier, T., Villa, D., Klasa, R.
Format: Artikel
Sprache:eng
Schlagworte:
Adult
Aged
Antibodies, Monoclonal, Murine-Derived - therapeutic use
Antineoplastic Combined Chemotherapy Protocols - therapeutic use
British Columbia - epidemiology
Cyclophosphamide - therapeutic use
Doxorubicin - therapeutic use
Drug Resistance, Neoplasm
Female
Hematology
Humans
Lymphoma, Large B-Cell, Diffuse - diagnosis
Lymphoma, Large B-Cell, Diffuse - drug therapy
Lymphoma, Large B-Cell, Diffuse - mortality
Lymphoma, Large B-Cell, Diffuse - pathology
Male
Medicine
Medicine & Public Health
Middle Aged
Oncology
Original Article
Prednisone - therapeutic use
Prognosis
Registries
Survival Analysis
Treatment Failure
Vincristine - therapeutic use
Young Adult
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Primary refractory diffuse large B cell lymphoma (DLBCL) following R-CHOP chemotherapy is a major concern. We identified 1126 patients with DLBCL treated with R-CHOP from 2000 to 2009, of whom 166 (15 %) had primary refractory disease. Of the 75/166 (45 %) who were age
ISSN:0939-5555
1432-0584
DOI:10.1007/s00277-015-2467-z